Status of the 25 Patients treated under the FDA EI
Post# of 153864
(Total Views: 585)
Posted On: 04/13/2020 8:20:26 AM
Re: Longestyard #27170
Status of the 25 Patients treated under the FDA EINDs?
Has the company reported the latest status of the 12+ patients treated at Albert Einstein's Motefiore Medical center? From today's press release of the 5 Southern CA patients treated under EINDs and last weeks' reported results in New York, it seems that there is an incredible story to be told on a growing number (25) of patients treated under "Emergency Use" but I seem to have missed it...
https://finance.yahoo.com/news/southern-calif...10470.html
Patient enrollment in the Company’s two clinical trials and Emergency Investigational New Drug (EIND) is as follows:
More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA).
Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen.
As of last week, 12 patients have been treated in the Phase 2 trial for mild-to-moderate COVID-19 indications and, because it is a double-blinded, placebo-controlled trial, results are not yet available.
First site cleared to enroll patients in Phase 2b/3 beginning today.
Has the company reported the latest status of the 12+ patients treated at Albert Einstein's Motefiore Medical center? From today's press release of the 5 Southern CA patients treated under EINDs and last weeks' reported results in New York, it seems that there is an incredible story to be told on a growing number (25) of patients treated under "Emergency Use" but I seem to have missed it...
https://finance.yahoo.com/news/southern-calif...10470.html
Patient enrollment in the Company’s two clinical trials and Emergency Investigational New Drug (EIND) is as follows:
More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA).
Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen.
As of last week, 12 patients have been treated in the Phase 2 trial for mild-to-moderate COVID-19 indications and, because it is a double-blinded, placebo-controlled trial, results are not yet available.
First site cleared to enroll patients in Phase 2b/3 beginning today.
(1)
(0)